/kg hematopoietic progenitor cells (HPC). These cells will be studied for cytogenetics and BCR-ABL/ ABL ratio and cryopreserved; in the meantime, the patient resumes Imatinib therapy until disease progression. In that phase, high-dose chemotherapy (eg busulfan) followed by previously collected Ph negative or predominantly Ph-negative HPC, will be given. After engraftment, the patient will be 'maintained' with IFN-a, since the progression occurred on Imatinib. If, on the contrary, the patient achieves CHR but not CCyR, we can stop Imatinib, start in vivo mobilization chemotherapy with mini-ICE+G-CSF, and collect HPC which can be used as 'rescue' after high-dose busulfan. 2 After engraftment, IFN-a will be offered to the patient. Our experience with five patients mobilized in the above conditions showed in three of them an excellent quality of the collected cells in terms of CD34+ cells (42 Â 10 6 /Kg), with a content of leukemic cells lower than those found in the bone marrow as measured by RT-PCR for BCR-ABL transcripts.
As recently stated, Imatinib has disclosed new intriguing possibilities but few would claim that it actually cures CML. [3] [4] [5] [6] We do not know if this drug blocks the proliferative advantage of Ph-positive cells 7 or whether it indeed leads to the demise of all Imatinib-sensitive cells. 8 The difference between Dr Luzzatto's and our opinion is that we consider it more useful to employ an intensified approach consisting of Imatinib and high-dose therapy with rescue with the best collected cells instead of conventional therapy (IFN-a, Ara-C, etc) combined with Imatinib as the possible pharmacological cure. Since no patient autografted in early-chronic phase by our team died of transplanted-related causes, 2 the combined approach (Imatinib-Autografting) could represent an important future perspective for patients who have adverse prognostic characteristics. 
TO THE EDITOR
Patients with myelodysplastic syndromes (MDS) have a particularly poor prognosis if their bone marrow cells show complex chromosomal aberrations. These patients rarely respond to cytotoxic or immunosuppressive treatment. Recently, thalidomide, a sedative drug with immunomodulatory and antiangiogenic properties, has emerged as a promising new treatment modality for patients with MDS.
1 Several patients with low-risk MDS have been reported to become independent of blood transfusions under thalidomide treatment. In some high-risk patients, the proportion of blast cells in the bone marrow decreased significantly. Here, we report on remarkable cytogenetic remissions in addition to normalization of blood counts in three patients with MDS. Two of these patients had a poor risk karyotype (monosomy 7 and complex karyotype, respectively) according to the IPSS, 2 while another patient had a 5qÀ anomaly.
Patient I
A 63-year-old man was admitted to our hospital for the first time in May 2000, because of anemia (7.8 g/dl) and thrombocytopenia (22 000/ml). The white blood count (WBC) was normal (7200/ml). The differential count showed four blasts, three monocytes, 20 neutrophils, 41 lymphocytes, nine eosinophils, and 23 basophils. Serum erythropoietin was increased to 1800 mU/ml (normal range 1.6-29.5 mU/ml). Bone marrow cytology showed hypercellularity, with hyperplasia of granulopoiesis (30%), a corresponding decrease of erythropoiesis (5%), and 21% blast cells. Megakaryopoiesis was sparse and dysplastic, with micromegakaryocytes and mononucleated megakaryocytes. Refractory anemia with excess of blasts (RAEB-T) was diagnosed, according to the FAB-classification. needed every 2 weeks, and platelet transfusions twice weekly. The patient was not fit enough to undergo high-dose chemotherapy and autologous stem cell transplantation. He agreed to participate in a trial of thalidomide and received 200 mg/d as single oral dose in the evening, starting on May 15, 2000. After 2 weeks, the dose was increased to 400 mg/d. No serious side effects were noted. On June 6, the patient was hospitalized because of a variceal bleeding from the prostate. Anemia (Hb 7.9 g/dl), leukocytosis (18 000/ml), and severe thrombocytopenia (6000/ml) were noted. He was treated with repeated platelet and red cell transfusions and urinary bladder irrigation. Thalidomide was continued at a daily dose of 400 mg. Without further transfusions, platelet counts increased slowly but steadily. In August 2000, the patient was discharged with platelets between 80 000 and 100 000/ml, and hemoglobin between 8.0 and 9.0 g/dl. After 1 week, he returned with progressive dyspnea and a swollen right leg. The platelet count was 153 000/ml. Venography revealed thrombosis of the right femoral vein, requiring full anticoagulant protection with heparin. Pulmonary perfusion scintigraphy showed several small perfusion defects, indicating pulmonary embolism as the cause of dyspnea. After 2 weeks, the patient was discharged with long-term anticoagulant protection (phenprocouron).
On October 5, 2000, he presented to our outpatient clinic with a WBC of 6000/ml, hemoglobin 12.8 g/dl, and platelets 240 000/ml.
The differential count showed 54 neutrophils, 13 monocytes, 27 lymphocytes, five eosinophils, and one basophil. Bone marrow cytology showed hypercellularity and erythroid hyperplasia (64%). Dysplastic features like binuclearity or multinuclearity were still present in erythroblasts. The proportion of blast cells was 5%. The number of megakaryocytes was normal, but micromegakaryocytes and other dysplastic features were noted. According to IWGcriteria, 4 partial remission was diagnosed. Chromosomal analysis of 20 metaphases showed a normal karyotype: 46, XY (Figure 2 ). The dose of thalidomide was reduced to 300 mg/d, since the patient complained of obstipation and fatigue.
In February 2001, blood counts started to deteriorate. In March, while still on thalidomide 300 mg/d, the patient presented with leukopenia (3100/ml), anemia (Hb 8.6 g/dl), and thrombocytopenia (31000/ml). The hypocellular marrow showed 25-30% blast cells. Megakaryopoiesis was sparse and dysplastic. RAEB-T was diagnosed again. On cytogenetic analysis, 15 metaphases appeared normal, while five metaphases showed a complex karyotype, with novel aberrations in addition to the changes found at diagnosis: 45, XY, del(2)(p13?4), add(4)(p11), À6, del(5)(q13q33), add(13)(p10), add(17)(p11), del(20)(q11) (Figure 3) . The patient first declined intensive chemotherapy, but later, in April 2001, received chemotherapy at another hospital near his hometown. Hematological remission was induced with daunorubicin, cytarabin and thioguanine. In August 2001, the patient underwent allogeneic stem cell transplantation as consolidation therapy. The conditioning regimen consisted of total body irradiation plus cyclophosphamide and treosulfan. HLA-identical peripheral blood stem cells were transplanted from his brother. The patient died of septic complications in August 2001.
Patient II
A 68-year-old woman with MDS was admitted to our hospital for the first time in July 2000, because of increased transfusion frequency (up to two packed red cell units every 2 weeks in the previous 3 months). Refractory anemia (RA) had been diagnosed in September 1999. In July 2000, she presented with anemia (7.2 g/dl) and leukocytopenia (2800/ml), while platelets were normal (245 000/ml). The differential count showed 48 neutrophils, three monocytes, 47 lymphocytes, one eosinophil, and one basophil. Serum erythropoietin was increased to 2580 mU/ml). Bone marrow cytology showed hypercellularity, with hyperplasia of erythropoiesis (40%), a corresponding decrease of granulopoiesis (5%), and Cytogenetics of Patient I at relapse: 15 metaphases showed a normal karyotype, whereas five metaphases showed a complex abnormal karyotype, characterized by novel aberrations in addition to the chromosomal changes found at diagnosis: 45, XY, del (2) (p13?4), add (4) (p11), À6, del (5) (q13q33), add (13) (p10), add (17) (p11), del (20) (p11).
Correspondence presence of micromegakaryocytes and mononucleated megakaryocytes. RA was diagnosed. An abnormal karyotype was detected in 11 out of 20 metaphases: 46, XX, del (5) (q22q33). The patient agreed to participate in a trial of thalidomide starting on August 1, 2000. Over 4 weeks, the dose was increased from 100 to 400 mg/d. The patient noted only mild fatigue, and thalidomide was continued at a daily dose of 400 mg. Hemoglobin slowly increased to 12.6 g/dl in January, 2001. Leukocytes increased to 4200/ml. Platelets remained basically unchanged. Partial remission was diagnosed according to IWG-criteria. The bone marrow showed erythropoietic hyperplasia and persisting trilineage dysplasia (RA). Only two out of XX metaphases displayed the abnormal karyotype (46, XX, del (5) (q22q33)). Thalidomide was gradually reduced to 200 mg/d. In April 2001, when the hemoglobin had decreased to 9.6 g/dl, thalidomide was increased to 400 mg/d. Subsequently, hemoglobin levels ranged between 9 and 11 g/dl without transfusions. Because of fatigue and constipation, the patient decreased the dose of thalidomide to 200 mg/d in October 2001. Hemoglobin continued to range between 9 and 10 g/dl, and WBC ranged between 3000 and 4000/ml. At the time of this writing, the patient has been transfusionindependent for 21 months.
Patient III
A 76-year-old woman was admitted to our hospital for the first time in July 2000 because of severe pancytopenia (WBC 1700/ml, Hb 7.1 g/dl, platelets 11 000/ml). She had been treated with methotrexate for rheumatoid arthritis from March 1992 until May 1999. She became transfusion-dependent in May 1999. Since then, transfusion requirement increased to 24 U of packed red cells and 22 U of platelets during the 3-month period prior to admission. The patient had also suffered multiple infectious complications.
The differential white count showed eight neutrophils, 84 lymphocytes, four eosinophils, and four basophils. The bone marrow was hypercellular, with erythropoietic hyperplasia and a corresponding decrease of granulopoiesis. Megakaryopoiesis was diminished and dysplastic. There were 4% blasts and 30% ringed sideroblasts. RA with ringed sideroblasts (RARS) was diagnosed. Karyotype analysis showed 20 abnormal metaphases: 45, XX, À7, del(12)(p12). Thalidomide was started on July 12, 1999. Over 4 weeks, the dose was increased from 100 to 300 mg/d. Mild fatigue and constipation were noted. Hemoglobin and platelets slowly increased and the patient became transfusion-independent in September 1999 (WBC 3600/ml, Hb 11.6 g/dl, platelets 42 000/ml). On cytological bone marrow examination (10/99), megakaryopoiesis remained dysplastic, with micromegakaryocytes and mononucleated cells. Apart from ringed sideroblasts (30%), erythropoiesis showed no significant dysplasia and granulopoiesis appeared normal. A normal karyotype (46, XX) was found in 20 metaphases. Since peripheral blood counts showed further improvement (WBC 10 000/ml, Hb 12.1 g/dl, platelets 129 000/ml), thalidomide was slowly reduced to 100 mg/d. In April 2000, thalidomide was discontinued because the patient complained of mild symptoms of peripheral neuropathy. Since that time, hemoglobin levels ranged between 12 and 13 g/dl, WBC 7000-10 000/ml, and platelet counts 110 000-150 000/ml. The patient has been independent of blood transfusions for 33 months at the time of this writing, and there is still no indication of relapse.
Discussion
In January 2002, we reported an interim analysis 1 of our thalidomide study, which started in July 1999. In the subgroup of patients with chromosomal abnormalities (n ¼ 16), a significant proportion (n ¼ 7, 44%) achieved partial remission or major hematological responses according to IWG criteria. With longer follow-up, we now report that among the 16 patients with karyotype anomalies, three achieved remarkable cytogenetic responses. This was accompanied by a major response of hematological parameters (according to IWG criteria) in two patients, and a minor response in one patient. Cytogenetic responses have apparently not been seen in other studies of thalidomide treatment for MDS and OMF. 5, 6 The mechanism of action of thalidomide in MDS is still unknown. The significant decrease in bone marrow blasts, which has been observed with thalidomide treatment in high-risk MDS, may not be attributable to a direct toxic effect on the malignant cells, but may depend on modulation of cell surface markers and the cytokine milieu. However, there is as yet no evidence that antiangiogenic properties of thalidomide or the suppression of TNF-a production are pivotal. Responding patients showed neither a significant decrease of microvessel density in the bone marrow nor a significant change in cytokines in serum and bone marrow. 7 Recent reports suggested that thalidomide and its analogs have T-cell costimulatory activities. 8 In our patients with MDS, thalidomide did not significantly change the CD4+/CD8+ ratio of T-cells (unpublished data).
Whatever the mechanism of thalidomide action, the persistence of dysplastic features during cytogenetic remission suggests that the bone marrow remained clonal and preleukemic. Therefore, the effect of thalidomide was probably most pronounced in the most advanced product of clonal evolution, that is, the predominant clone featuring the chromosomal abnormalities detected by conventional cytogenetics.
The present cases demonstrate that a trial of thalidomide should not be regarded as futile even in the presence of complex chromosomal aberrations. In order to achieve a higher rate of complete hematological and cytogenetic remissions, and perhaps a longer duration of response, thalidomide might be combined with cytotoxic drugs or other treatment modalities. Immunology, Heinrich-Heine-University, Düsseldorf, Germany; 2 Department of Human Genetics, Heinrich-HeineUniversity, Düsseldorf, Germany
